Ethics roundtable: Using new, expensive drugs
Costly genetically engineered therapies, which threaten to cripple the health care industry economy and undermine the common good if applied indiscriminately, loom on the horizon. The spectrum of applicable candidates include moribund nursing home patients at the end of life. They will be fair game...
Gespeichert in:
| Veröffentlicht in: | Critical care (London, England) England), 2002-12, Vol.6 (6), p.473-478 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 478 |
|---|---|
| container_issue | 6 |
| container_start_page | 473 |
| container_title | Critical care (London, England) |
| container_volume | 6 |
| creator | Burrows, Richard Crippen, David Dellinger, R Phillip Kelly, David F Streat, Stephen Whetstine, Leslie M |
| description | Costly genetically engineered therapies, which threaten to cripple the health care industry economy and undermine the common good if applied indiscriminately, loom on the horizon. The spectrum of applicable candidates include moribund nursing home patients at the end of life. They will be fair game for therapy that will ultimately send them back to nursing homes to return later with the same condition. 'Quality of life' assessments that limit patient autonomy may be forced as a result. Discussants from South Africa, New Zealand, and the USA suggest methods to deal with this issue in a just and ethical framework. |
| doi_str_mv | 10.1186/cc1533 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_153428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72783116</sourcerecordid><originalsourceid>FETCH-LOGICAL-b370t-5b972775ec6e831d12a4fc2540376bfb35c42a2110aaf4c45d0f1b08fd96f183</originalsourceid><addsrcrecordid>eNp1UU1LAzEQDaLYWvUnyOLBk6v53l3Bg5T6AQUvFbyFJJttU3aTutmt-u-NtIoKnmZg3nsz7w0AxwheIJTzS60RI2QHDBHlPOWweN6NPeE0zRlhA3AQwhJClOWc7IMBwrQgkGdDkE66hdUhaX3vyk6q2lwlT8G6eeLM63li3lbGBbs2Sdn283AI9ipZB3O0rSMwu53Mxvfp9PHuYXwzTRXJYJcyVWQ4y5jR3OQElQhLWmnMKCQZV5UiTFMsMUJQyopqykpYIQXzqix4hXIyAtcb2VWvGlNq47pW1mLV2ka278JLK35PnF2IuV-LmAHFn_xiw1fW_8P_PdG-EZsEI_dsu7v1L70JnWhs0KaupTO-DyIai5YQj8DTP8Cl71sXYxGoYJQxGvVG4OSnk-8Tvh5APgBG_Yc3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195455415</pqid></control><display><type>article</type><title>Ethics roundtable: Using new, expensive drugs</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>SpringerLink Journals - AutoHoldings</source><creator>Burrows, Richard ; Crippen, David ; Dellinger, R Phillip ; Kelly, David F ; Streat, Stephen ; Whetstine, Leslie M</creator><creatorcontrib>Burrows, Richard ; Crippen, David ; Dellinger, R Phillip ; Kelly, David F ; Streat, Stephen ; Whetstine, Leslie M</creatorcontrib><description>Costly genetically engineered therapies, which threaten to cripple the health care industry economy and undermine the common good if applied indiscriminately, loom on the horizon. The spectrum of applicable candidates include moribund nursing home patients at the end of life. They will be fair game for therapy that will ultimately send them back to nursing homes to return later with the same condition. 'Quality of life' assessments that limit patient autonomy may be forced as a result. Discussants from South Africa, New Zealand, and the USA suggest methods to deal with this issue in a just and ethical framework.</description><identifier>ISSN: 1364-8535</identifier><identifier>EISSN: 1466-609X</identifier><identifier>DOI: 10.1186/cc1533</identifier><identifier>PMID: 12493067</identifier><language>eng</language><publisher>England: National Library of Medicine - MEDLINE Abstracts</publisher><subject>Aged ; Aged, 80 and over ; Bioethics ; Decision Making - ethics ; Drug Costs ; Drug Utilization - economics ; Drug Utilization - ethics ; Ethics, Clinical ; Health Policy ; Humans ; Male ; Professional-Family Relations ; Quality of Life ; Resource Allocation ; Sepsis - drug therapy ; United States ; Value of Life - economics</subject><ispartof>Critical care (London, England), 2002-12, Vol.6 (6), p.473-478</ispartof><rights>Copyright National Library of Medicine - MEDLINE Abstracts Dec 2002</rights><rights>Copyright © 2002 BioMed Central Ltd 2002 BioMed Central Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC153428/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC153428/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,309,310,314,727,780,784,789,790,864,885,23928,23929,25138,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12493067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burrows, Richard</creatorcontrib><creatorcontrib>Crippen, David</creatorcontrib><creatorcontrib>Dellinger, R Phillip</creatorcontrib><creatorcontrib>Kelly, David F</creatorcontrib><creatorcontrib>Streat, Stephen</creatorcontrib><creatorcontrib>Whetstine, Leslie M</creatorcontrib><title>Ethics roundtable: Using new, expensive drugs</title><title>Critical care (London, England)</title><addtitle>Crit Care</addtitle><description>Costly genetically engineered therapies, which threaten to cripple the health care industry economy and undermine the common good if applied indiscriminately, loom on the horizon. The spectrum of applicable candidates include moribund nursing home patients at the end of life. They will be fair game for therapy that will ultimately send them back to nursing homes to return later with the same condition. 'Quality of life' assessments that limit patient autonomy may be forced as a result. Discussants from South Africa, New Zealand, and the USA suggest methods to deal with this issue in a just and ethical framework.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bioethics</subject><subject>Decision Making - ethics</subject><subject>Drug Costs</subject><subject>Drug Utilization - economics</subject><subject>Drug Utilization - ethics</subject><subject>Ethics, Clinical</subject><subject>Health Policy</subject><subject>Humans</subject><subject>Male</subject><subject>Professional-Family Relations</subject><subject>Quality of Life</subject><subject>Resource Allocation</subject><subject>Sepsis - drug therapy</subject><subject>United States</subject><subject>Value of Life - economics</subject><issn>1364-8535</issn><issn>1466-609X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UU1LAzEQDaLYWvUnyOLBk6v53l3Bg5T6AQUvFbyFJJttU3aTutmt-u-NtIoKnmZg3nsz7w0AxwheIJTzS60RI2QHDBHlPOWweN6NPeE0zRlhA3AQwhJClOWc7IMBwrQgkGdDkE66hdUhaX3vyk6q2lwlT8G6eeLM63li3lbGBbs2Sdn283AI9ipZB3O0rSMwu53Mxvfp9PHuYXwzTRXJYJcyVWQ4y5jR3OQElQhLWmnMKCQZV5UiTFMsMUJQyopqykpYIQXzqix4hXIyAtcb2VWvGlNq47pW1mLV2ka278JLK35PnF2IuV-LmAHFn_xiw1fW_8P_PdG-EZsEI_dsu7v1L70JnWhs0KaupTO-DyIai5YQj8DTP8Cl71sXYxGoYJQxGvVG4OSnk-8Tvh5APgBG_Yc3</recordid><startdate>20021201</startdate><enddate>20021201</enddate><creator>Burrows, Richard</creator><creator>Crippen, David</creator><creator>Dellinger, R Phillip</creator><creator>Kelly, David F</creator><creator>Streat, Stephen</creator><creator>Whetstine, Leslie M</creator><general>National Library of Medicine - MEDLINE Abstracts</general><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20021201</creationdate><title>Ethics roundtable: Using new, expensive drugs</title><author>Burrows, Richard ; Crippen, David ; Dellinger, R Phillip ; Kelly, David F ; Streat, Stephen ; Whetstine, Leslie M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b370t-5b972775ec6e831d12a4fc2540376bfb35c42a2110aaf4c45d0f1b08fd96f183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bioethics</topic><topic>Decision Making - ethics</topic><topic>Drug Costs</topic><topic>Drug Utilization - economics</topic><topic>Drug Utilization - ethics</topic><topic>Ethics, Clinical</topic><topic>Health Policy</topic><topic>Humans</topic><topic>Male</topic><topic>Professional-Family Relations</topic><topic>Quality of Life</topic><topic>Resource Allocation</topic><topic>Sepsis - drug therapy</topic><topic>United States</topic><topic>Value of Life - economics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burrows, Richard</creatorcontrib><creatorcontrib>Crippen, David</creatorcontrib><creatorcontrib>Dellinger, R Phillip</creatorcontrib><creatorcontrib>Kelly, David F</creatorcontrib><creatorcontrib>Streat, Stephen</creatorcontrib><creatorcontrib>Whetstine, Leslie M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Critical care (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burrows, Richard</au><au>Crippen, David</au><au>Dellinger, R Phillip</au><au>Kelly, David F</au><au>Streat, Stephen</au><au>Whetstine, Leslie M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ethics roundtable: Using new, expensive drugs</atitle><jtitle>Critical care (London, England)</jtitle><addtitle>Crit Care</addtitle><date>2002-12-01</date><risdate>2002</risdate><volume>6</volume><issue>6</issue><spage>473</spage><epage>478</epage><pages>473-478</pages><issn>1364-8535</issn><eissn>1466-609X</eissn><abstract>Costly genetically engineered therapies, which threaten to cripple the health care industry economy and undermine the common good if applied indiscriminately, loom on the horizon. The spectrum of applicable candidates include moribund nursing home patients at the end of life. They will be fair game for therapy that will ultimately send them back to nursing homes to return later with the same condition. 'Quality of life' assessments that limit patient autonomy may be forced as a result. Discussants from South Africa, New Zealand, and the USA suggest methods to deal with this issue in a just and ethical framework.</abstract><cop>England</cop><pub>National Library of Medicine - MEDLINE Abstracts</pub><pmid>12493067</pmid><doi>10.1186/cc1533</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1364-8535 |
| ispartof | Critical care (London, England), 2002-12, Vol.6 (6), p.473-478 |
| issn | 1364-8535 1466-609X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_153428 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aged, 80 and over Bioethics Decision Making - ethics Drug Costs Drug Utilization - economics Drug Utilization - ethics Ethics, Clinical Health Policy Humans Male Professional-Family Relations Quality of Life Resource Allocation Sepsis - drug therapy United States Value of Life - economics |
| title | Ethics roundtable: Using new, expensive drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T15%3A36%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ethics%20roundtable:%20Using%20new,%20expensive%20drugs&rft.jtitle=Critical%20care%20(London,%20England)&rft.au=Burrows,%20Richard&rft.date=2002-12-01&rft.volume=6&rft.issue=6&rft.spage=473&rft.epage=478&rft.pages=473-478&rft.issn=1364-8535&rft.eissn=1466-609X&rft_id=info:doi/10.1186/cc1533&rft_dat=%3Cproquest_pubme%3E72783116%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195455415&rft_id=info:pmid/12493067&rfr_iscdi=true |